Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nektar Therapeutics

www.nektar.com

Latest From Nektar Therapeutics

Pipeline Watch: LentiGlobin, BMS-986205 Phase III Studies Initiated

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Nektar's IL-2 Impresses In Combination With Bristol's Opdivo

Nektar's IL-2 stimulating agonist NKTR-214 combines well with Bristol's Opdivo in Phase I PIVOT-02 study presented at SITC meeting in November.

ImmunoOncology Cancer

Bayer's Inhaled Cipro For Bronchiectasis To Face FDA Panel Efficacy Questions

Advisory committee asked to opine on whether there is substantial evidence of efficacy even though Phase III studies missed on three of four primary efficacy measures; Bayer argues that totality of the evidence demonstrates a meaningful benefit in reducing exacerbations in a heterogeneous patient population with the rare disease.

Advisory Committees Drug Review

Bristol's Strong SITC: IDO, 1L Kidney Cancer And New Mechanism Data Bode Well

In the CheckMate 214 study in first-line renal cell carcinoma, Bristol's Opdivo/Yervoy combo beat Pfizer's Sutent on overall survival endpoint regardless of PD-L1 expression, supporting a bid for expanded labeling.

ImmunoOncology Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Immune Disorders
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Inhale Therapeutic Systems Inc.
  • Nektar Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Nektar Therapeutics
  • Senior Management
  • Howard W Robin, Pres. & CEO
    Gil M Labrucherie, SVP, CFO
    John Nicholson, SVP, COO
    Stephen K Doberstein, PhD, SVP, CSO
    Ivan Gergel, MD, SVP, Drug Dev. & CMO
  • Contact Info
  • Nektar Therapeutics
    Phone: (415) 482-5300
    455 Mission Bay Blvd. S.
    San Francisco, CA 94158
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register